Dr. Reddy's Options Turn Defensive Before Thursday Print

Dr. Reddy's Laboratories heads into its October 23 quarterly results with options markets signalling a notably more cautious stance than usual, even as short sellers ease their positions in the lending market.

The most pointed signal ahead of the print is in options. The put/call ratio jumped to 1.07 on October 19, well above its 20-day average of 0.64, placing it just below the 52-week high of 1.23. That shift represents more than one standard deviation above the recent norm, pointing to heavier demand for downside protection than the stock has typically seen. It follows a month that has actually been kind to the shares, up 7.3% over 30 days to $13.08, with a further 2% gain on the week. The contrast between rising prices and rising put demand is the clearest tension heading into Thursday.

Short selling tells a less alarming story than the options market implies. Estimated short shares rose about 4% over the past week and 12% over the past month, but with borrow availability sitting at 120%, there is plenty of capacity for new shorts without any squeeze pressure. Cost to borrow has eased to around 0.6%, down nearly 30% over the past month, confirming the lending market is relaxed rather than stressed. The ORTEX short score dipped to 57 from 64 earlier in the week, a move in the right direction for bulls, though not a dramatic reversal.

The analyst picture is complicated by a currency mismatch in the data. The most recent meaningful move came from Citigroup on September 29, upgrading RDY from Sell to Buy and lifting its target sharply, though that target appears to be denominated in Indian rupees rather than US dollars given the ADR structure. The broader consensus sits at hold, with one outperform alongside it. Bulls point to an improving EPS trajectory, with the forward earnings estimate ranked in the 69th percentile for year-on-year growth, and a dividend score at the 94th percentile. Bears continue to focus on North American generics pricing pressure and the margin compression that has defined recent quarters, a theme that has weighed on the stock's momentum rank relative to domestic Indian pharma peers such as Sun Pharma and Cipla.

Ownership is anchored by founder-related stakes. K. Satish Reddy holds a 13D/A position representing about 13.6% of shares, and Kallam Reddy and Gunupati Prasad together account for a further 26% in the institutional register. These are strategic, stable stakes rather than activist catalysts. Among institutional managers, ICICI Prudential added roughly 5.8 million shares through August, and PPFAS added 845,000, suggesting some domestic Indian fund interest remains constructive. The 13D disclosure for K. Satish Reddy dates to September 2025, and as always with such filings, stakes are as last disclosed and holders dropping below 5% may exit without further notice.

Thursday's print will test whether the company's cost-control efforts have been enough to defend margins in North American generics, and whether the recent share price recovery reflects genuine operational improvement or simply a relief rally ahead of numbers.